Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (14031)	7/10/2000 7:50:17 PM
From: Cacaito	Read Replies (2) \| Respond to of 17367

A lot about nothing! Lilly's zovant/bpi combo is just generic all over patent claims coverage! If at all WORSE for xoma! xoma should have being the one to made the claim first! Did they? that should be your search!: xoma bpi/protein c combination claims!!! The claim belongs to Lilly, albeit I think if Lilly "ever" try to developed a combination product they will give some crumbs to xoma, you know enough to keep aforementioned salaries ongoing, and the incumbents will be more than happy. Not the shareholders! Lilly has the BIG upperhand! Another xoma flop! The nightmare is now a dayghtmare!